At present, medical treatments for breast cancer have been intensified with the standard use of anthracyclines in chemotherapy, anti-HER2 targeted therapy, and long-term hormonotherapy, which might help to improve locoregional control in postmastectomy patients. This evidence concerns the gene ERBB2 and breast carcinoma.